As the reliability of malignant hyperthermia normal in vitro contracture test results has been questioned, this study set out to determine the reliability of malignant hyperthermia normal results in New Zealand. Three hundred and twentynine anaesthetics were administered to malignant hyperthermia normal patients, identified through the Palmerston North Hospital malignant hyperthermia database. Anaesthetic records were retrieved and scrutinised for a malignant hyperthermia reaction using the Malignant Hyperthermia Clinical Grading Scale. Patients were exposed to one or more of eight triggering agents and multiple anaesthetic agents were administered in 41% of cases. Six variables were analysed, and although a minority of variables were abnormal in a small number of patients, none of the findings supported a malignant hyperthermia reaction. While the analysis was limited by the adequacy of the anaesthesia records, it was supported by negative DNA analysis in 55% of patients. This study supports several previous studies in demonstrating that patients in New Zealand tested non-susceptible to malignant hyperthermia can safely be given triggering agents.
Malignant hyperthermia (MH) is an uncommon, inherited, hypermetabolic disorder caused by dysfunctional calcium homeostasis in skeletal muscle. It is triggered almost exclusively by potent anaesthetic inhalational agents and depolarising muscle relaxants. The consistent presence of extreme hyperthermia and high mortality (>70%) in the earlier years led to the name 1 .
The gold standard for testing potentially susceptible patients is the in vitro contracture test (IVCT) of a muscle biopsy [2] [3] [4] . The test is invasive, requiring excision of a segment of muscle from the lateral quadriceps and can cause some morbidity 5 . Current anaesthetic agents are relatively free of side-effects and so administration of trigger-free anaesthesia is more straightforward than previously. Therefore, there must be good reasons to test for MH susceptibility. Testing is necessary as a wider pool of possible MH susceptible individuals will develop rapidly if testing is abandoned. This will mean an increasing number of patients will not have the full range of anaesthesia available to them. Volatile anaesthetics are particularly useful in some situations such as inhalational induction in an infant when difficulty with intravenous access is encountered, repeat anaesthetics in young children, radiology procedures in young children and epiglottitis management. The use of suxamethonium may also be strongly indicated in the event of laryngospasm. However, while rocuronium does not give as good intubating conditions as suxamethonium, the problem with reversal has been bypassed by the introduction of sugammadex 6 .
Many patients want to know if they are affected by this disorder. They do not want lifelong attachment to a MedicAlert ® (MedicAlert ® Foundation New Zealand Inc., Upper Hutt, New Zealand) emblem and their careers may be affected, e.g. army personnel may be limited in the scope of their employment. Travellers in a developing country may be affected by inadequate supplies of currently used anaesthetics. Marriage prospects may also be affected in individuals with a genetic disorder, particularly in some Asian countries 7 . These factors may all affect the lifestyle of the patient. Trigger-free anaesthetics are more expensive than normal anaesthetics. For instance, 'cleaning' an anaesthetic machine (Aestiva, Aisys, GE Healthcare, Chalfont St Giles, Buckinghamshire, UK) 8 requires a flushing time of 55 minutes and a subsequent constant flow of oxygen at 10 l/minute for the duration of the operation, as well as fresh soda lime, charcoal filters if used and increased theatre preparation time and staffing.
A negative or normal test (MHN) however, confirms that the individual is not susceptible to MH. The reliability of the MHN result has been questioned and there have been reports of false negative results. On the other hand, there have been no reports, anecdotal or otherwise, of false negative IVCT results in New Zealand. This study set out to determine the reliability of MHN results in New Zealand by retrospective analysis.
MATERIALS AND METHODS
Ethics approval for this study was obtained from the Multi-region Ethics Committee, Ministry of Health, Wellington.
Patient population
Palmerston North is the New Zealand national testing centre for patients suspected of malignant hyperthermia. A database was established in 1991 which contains all known families affected by MH in New Zealand. From this database, MHN individuals and their relatives and descendants were contacted and hospital records were obtained to document anaesthetic data. Children, grandchildren and more distant generations of MHN individuals are regarded as immediate relatives and are considered not susceptible to MH.
If an MHN individual or immediate relative had received a triggering agent, the following data were recorded. 
In vitro contracture test and DNA testing
The IVCT is conducted according to the European MH group protocol 3 . Results are divided into three categories -MHS (susceptible), MHN (normal) and MHE (equivocal) 3 .
Analysis of DNA was undertaken at Massey University, Palmerston North. Blood samples were taken after obtaining informed consent. Ethical approval was obtained from the Central Region Human Ethics committee. DNA was extracted from whole blood using the Promega Wizard™ (Promega Corp., Madison, Wisconsin, USA) genomic DNA purification kit according to the manufacturer's instructions. Familial mutations were identified by polymerase chain reaction-amplification of RYR1 sequences from genomic DNA using allele-specific assays with hybridisation probes and real-time polymerase chain reaction on the Roche Lightcycler 1.2. Primer and probe sequences are available from the authors (KS) on request.
Malignant Hyperthermia Clinical Grading Scale
The MHCGS was developed in 1994 and ranks the likelihood that an adverse anaesthetic event represents MH 9 . Signs of an MH reaction are non-specific and the lack of a precise clinical definition has led to poor prediction of MH susceptibility by clinical criteria alone. To improve prediction, a group of MH experts created a multifactorial MH scale using standardised clinical criteria (Tables 1 and 2 ). Points are assigned to specific abnormal signs and laboratory findings (clinical indicators) and then summed to produce a score which translates to an MH rank designating the likelihood that this adverse event was MH. This ranges from 1 (almost never) to 6 (almost certain). Each anaesthetic was ranked using the MHCGS.
Statistics
Descriptive statistics (mean and range) of intraoperative, PACU and ward data are presented. Age range, mean age and intraoperative time are also presented.
Confidence intervals for zero numerator proportions were derived using the following link -http://statpages.org/confint.html. This computes exact confidence intervals from binomial distributions and calculates 95% confidence intervals.
RESULTS
A negative IVCT result was documented in only 37 of the 51 known MH susceptible families in New Zealand. In nine of these 37 families, MHN patients or immediate relatives had not been administered triggering agents or family members could not be contacted. Therefore, members of 28 families are represented in this MHN study. Consent forms were sent to 348 MHN individuals and replies were received from 172 (49.4%). All MHN parents contacted regarding anaesthetics in their children received a consent form, and verbal consent was obtained to review the child's anaesthetic records for 69 individuals.
Anaesthetics administered
A total of 329 anaesthetics with known triggering agents were administered to 165 MHN patients or their immediate relatives. The 165 patients were subdivided into 116 MHN patients and 49 immediate relatives. All anaesthetics were undertaken between 1979 and early 2008. Approximately 8% of anaesthetics were undertaken before 1991. Of the total 329 anaesthetics, 241 were administered to MHN patients and 88 to immediate relatives. The anaesthetics in immediate relatives were further subdivided into 68 children and 20 grandchildren or great-grandchildren of MHN patients.
Triggering agents used are shown in Table 3 . Sevoflurane was the most commonly used volatile agent (41%). Halothane was used in 71 cases (22%), but usage of this agent declined from the early 1990s. Isoflurane was used in 87 cases (27%), but has decreased in use since the early 2000s. Only 47 anaesthetics included a combination of suxamethonium plus an inhalational agent (15%), of which 15 included halothane, 12 sevoflurane and 16 isoflurane. In two anaesthetics suxamethonium was the only triggering agent used. The longest duration of anaesthesia with a combination of suxamethonium and an inhalational agent was 3 hours and 45 minutes. Triggering agents were recorded in another 20 anaesthetic records, but these were so inadequate that they have not been included in this study.
Of the 165 patients, 98 received one triggering anaesthetic (59%), 34 had two exposures (21%) and 33 (20%) three or more exposures. One patient received eight exposures to triggering agents. This patient was an adult with negative DNA analysis who received a combination of suxamethonium and three different potent inhalational agents.
Anaesthesia duration ranged from 10 minutes to 10.5 hours (mean 69 minutes). Ages ranged from 
Observations
The creatine kinase was measured in two cases. Reported creatine kinase results were 319 IU (n=20-215) in a patient who had suxamethonium during induction for an open reduction internal fixation of mandible and 147 IU for a patient having an appendicectomy. Potassium was measured in 13 cases. Measurements ranged from 2.9 to 5.0 mmol/l. Arterial blood gases were measured in 11 cases. The maximum base deficit recorded was 1.8 mmol/l.
Intraoperative recordings are shown in Table 4 . Peak recordings of each variable were noted except for SpO 2 where the lowest recording was documented. Many anaesthetic records were incomplete, particularly the older records.
Complete records, i.e. with six variables recorded (or five with ward recordings as ETCO 2 were not included there), were present in 56 intraoperative records. There were 85 records with one variable omitted, and 184 with more than one omitted. Similar data were obtained from PACU and following discharge from PACU (day of surgery or ward) groups.
Intraoperatively, 33 adult patients had an abnormal heart rate at some point during anaesthesia. Respiratory rate was >26 /minute in nine paediatric patients (<15 years age) and >20 /minute in two adult patients. These two patients had a thoracotomy and bilateral venting tubes. T° was increased (>38°C) in five adults (all had appendicetomies) and two children. In one child, the temperature increase was during an ophthalmic procedure and the other during a laparoscopic appendicectomy. Five of the seven patients had a T° >38.8°C. The ETCO 2 was >55 mmHg in nine children breathing spontaneously and in seven adults. Six of the seven adults were breathing spontaneously during the procedure. There were no other signs of MH. An SpO 2 <95% was recorded in eight adult patients.
Similar analysis was undertaken for PACU data. Abnormal recordings were obtained in individuals but overall no evidence of MH was noted ( Table 5) . Similar results were obtained for day of surgery unit or ward data.
Malignant Hyperthermia Clinical Grading Scale
Each anaesthetic was ranked using the MHCGS: 235 ranked 1 indicating an 'almost never' likelihood of an MH reaction, 66 ranked 2 indicating an MH reaction was unlikely and 28 ranked 3, 'somewhat less than likely' risk of MH (Figure 1 ). The majority of rank 2 scored points on the basis of an inappropriate tachycardia, usually at induction. An increase in RR and occasionally increased ETCO 2 unrelated to hypermetabolism resulted in a rank of 3 in 28 anaesthetics.
Similar recordings were analysed from PACU observations ( Figure 2 ). Some abnormal individual variables were found: 243 ranked 1, 54 ranked 2, 31 ranked 3 and one ranked 4. The increased ranking in these patients was mainly on the basis of tachycardia and either pyrexia or increased RR. One three-year-old patient ranked 4 but there were other explanations for the abnormal signs.
Other analysis
Nine different causative RYR1 mutations had been identified in families of patients who had been administered the 329 triggering anaesthetics. DNA analysis was available for 179 (55%) triggering anaesthetics. DNA negative results were obtained in all patients. There was no discordance between IVCT and DNA analysis. Thirty-three percent or 111 anaesthetics were undertaken in Palmerston North Hospital. In the region around that hospital a large susceptible MH family is based. The larger New Zealand centres provided the remainder of the anaesthetics. Only 31 anaesthetic records were obtained from private hospitals.
Using binomial distributions, if 329 trigger anaesthetics were administered, 95% confidence intervals for the probability of MH are 0 to 1.12%. However the anaesthetics were administered to 165 patients so the confidence interval may be as wide as 0 to 2.2%. This analysis indicates that the risk is most likely zero, but might be as high as 2%.
DISCUSSION
In this study, 329 triggering anaesthetics were analysed in 116 MHN patients and 49 immediate relatives with no evidence of an MH reaction. These observations support those of smaller previous studies, and more importantly, confirm the diagnostic accuracy of a negative contracture test. The data suggest that it is safe to administer triggering agents to patients tested MHN. There have been five similar but smaller previous studies. Ording 10 When this data is pooled with the present study, 232 patients have received 429 anaesthetics with triggering agents. (Statistical analysis, 95% confidence intervals using binomial distributions calculate the probability of an MH reaction as 0 to 1.56% and 0 to 0.87% in patients and anaesthetics respectively).
Early signs of MH are indistinguishable from the normal physiological response to surgery. Patients, especially children will have a tachycardia or increased respiratory rate in response to pain. Fever around the time of surgery is common, especially for appendicectomy 15 . An increase in ETCO 2 will occur if there is inadequate ventilation or as a result of druginduced respiratory depression, secondary to opioid drugs. It is to be expected that some patients will show abnormal signs during surgery, as documented in Tables 4 and 5 . Peak findings included intraoperative heart rate 176 bpm, RR 60/minute, T° 39.3°C and ETCO 2 69 mmHg in individual patients (Table 4) .
When patients were ranked using the MHCGS, 72% ranked 1 indicating an 'almost never' likelihood of an MH reaction. A further 20% ranked 2, usually on the basis of a tachycardia (usually at induction) or an increased RR (especially in children). These findings were similar in PACU and both probably resulted from anxiety. A ranking of 2 gives an 'unlikely' likelihood of an MH reaction 9 . Of the remainder, 8% ranked 3 with a 'somewhat less than likely' likelihood of a reaction and this was usually on the basis of increased temperature, particularly in children, and tachycardia or tachypnoea, again likely related to anxiety. Several patients had an increased ETCO 2 , mainly caused by hypoventilation and there was no other evidence of hypermetabolism.
One child achieved a ranking of 4 indicating 'a somewhat greater than likely risk of MH' with sepsis as the most likely diagnosis. This child had a tonsillectomy and was found to have otitis media with bilateral ear infections. She had a temperature of 39.3°C, with tachycardia and tachypnoea (RR 60 /minute). She was treated with paracetamol and antibiotics and her signs settled after a few hours. Dantrolene was not administered to any patient.
Measurement of ETCO 2 is difficult to record in PACU but was documented for a few patients in Palmerston North Hospital. Temperatures were measured for the first four hours after return to the ward. Two studies found no evidence that an MH reaction can develop after the patient has been assessed as stable and discharged from PACU 16, 17 . The postoperative data in this study provides further confirmation of this.
All potent inhalational anaesthetics have triggered MH reactions 18 . Halothane is the most potent trigger of an MH reaction in vivo 19, 20 and in vitro 22 and in this study 22% were exposed to this agent. A study by Horbaschek et al 21 found that sevoflurane in vitro produced weaker contractures than halothane and isoflurane, but Yuge et al 22 found more potent effects in vivo. The mean anaesthetic time for patients in this study was 69 minutes, with exposure of the study group to eight different triggering agents. The mean time for triggering an MH reaction 23 (from induction to initial sign of a reaction) is 48 minutes (unpublished data, N. Pollock). This is less than the mean time of 69 minutes for the 329 procedures indicating adequate exposure to trigger an MH reaction.
Uncertainty regarding the reliability of MHN diagnoses has developed from reports of false negative IVCT diagnoses and discordance. The anaesthetic literature contains 10 reports of false negative IVCT results although all but one or two can be explained by alternative diagnoses. Isaacs et al 24 reported four patients, exposed to triggering anaesthetics after normal muscle biopsies, who developed clinical evidence of MH but the specimens were not tested according to a standard protocol. Wedel and Nelson 25 reported four children 10 years of age and younger with clinical MH who had muscle biopsies which were positive only to a combined halothane caffeine test but not caffeine or halothane alone. This combined test is no longer part of the North American MH group protocol. The children were aged six to 10 years. Ellis et al reported inconsistent responses in children less than 10 years of age because of muscle immaturity 26 . The muscle biopsy result can be questioned on this basis. All New Zealand muscle biopsies are carried out after 10 years of age.
Ording et al 27 found one of 105 patients with rank 5 or 6 using the MHCGS tested MHN, but this patient also had a concurrent myopathy that may have resulted in a clinical presentation similar to MH. In a smaller study, Allen et al 28 noted one of 32 patients with a similar finding. The IVCT results have been found to be abnormal in certain neuromuscular disorders 29, 30 . Therefore, in all but one of these reports an alternative diagnosis is possible, while clinical details are not available for the remaining report. The alternative diagnoses however, do not appear to have been fully accepted as in some countries the majority of anaesthetists accept only those IVCT results that demonstrate that the patient is MH susceptible (i.e. they do not accept MHN IVCT results 31 . This indicates that a minority of IVCT results may be false positive and this is a limitation of this biological test -increased sensitivity to reduce false negative test results may lead to an increased false positive rate.
MHN individuals with positive DNA tests (discordant) are potentially at risk. Although there are no known reports of MH reactions in patients with this diagnostic scenario 32 , these patients must be regarded as susceptible to MH. False negative diagnoses are more likely to have potentially fatal consequences under anaesthesia than false positive diagnoses 33 . This may suggest that diagnostic criteria are conservative in New Zealand minimising false negative MHN results at the expense of false positive results, but it does give increased confidence in administering triggering agents to MHN patients and their offspring.
The MHCGS was used to estimate the likelihood that abnormal observations were the result of developing MH. The MHCGS has limitations, especially in the absence of complete monitoring data as discussed above. There were however, no further developments to suggest MH even when patients were followed for four hours postoperatively. Offspring of MHN individuals are considered not susceptible to MH. In general, only one parent is tested, leaving the possibility that the other parent could be MH susceptible. This would make unexpected MH reactions more likely in the descendants of MHN individuals. This, however, has not occurred and there has been no evidence in New Zealand that the non-tested parent may be susceptible.
Another scenario that should be mentioned is the extremely unlikely possibility of a false negative test result. As inheritance is autosomal dominant, there would be a 50% chance that the child of the affected individual would be MH susceptible and a 25% chance that a grandchild would be susceptible. As has been discussed above, there is no evidence of this in New Zealand.
Larach et al published a paper in which a patient had 30 anaesthetics before triggering 34 . This patient had a hypermetabolic reaction with isoflurane as the trigger but there is no record of muscle biopsy or DNA analysis. This would appear to be an exceptional scenario as Larach et al also found that in 152 patients the mean number of anaesthetics before triggering was two 34 , a result similar to the study of Strazis et al 35 . In this current MHN study, 41% had multiple anaesthetics with triggering agents, without evidence of an MH reaction.
In conclusion, both the findings of this study and previous experience with MHN patients indicate that these patients can be safely given triggering agents in subsequent anaesthetics without risk of developing MH.
